Nikhil Munshi
Dana-Farber Cancer Institute- Medical Oncology- Boston MA-USA · Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nikhil Munshi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01222286 · Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple MyelomaInnate Pharma · completed · Smoldering Multiple Myeloma · principal investigator
- Ph1NCT00425347 · Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple MyelomaFacet Biotech · completed · Multiple Myeloma · principal investigator
- Ph2NCT00165347 · Protein Tyrosine Kinases (PTK) in Multiple MyelomaDana-Farber Cancer Institute · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 13 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Molecular Manipulation to Enhance Anti-Myeloma ResponseI01BX001584 · VA · VA BOSTON HEALTH CARE SYSTEM · fiscal years 2013 to 2027Same name and institution; not confirmed by an ID
- Core 1: Administrative CoreP01CA155258 · NCI · DANA-FARBER CANCER INST · fiscal years 2011 to 2026 · $161,714 awarded in 2026Same name and institution; not confirmed by an ID
- Decoding regulatory variants in cardiovascular diseaseR01HL181047 · NHLBI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · fiscal years 2026 · $849,790 awarded in 2026Same name and institution; not confirmed by an ID
- SPORE in Multiple MyelomaP50CA100707 · NCI · DANA-FARBER CANCER INST · fiscal years 2008 to 2023 · $2,257,199 awarded in 2023Same name and institution; not confirmed by an ID
- ShEEP request for next generation sequencing systemIS1BX005034 · VA · VA BOSTON HEALTH CARE SYSTEM · fiscal years 2019Same name and institution; not confirmed by an ID
- ShEEP Request for BD FACSAria Fusion Cell Sorting Flow CytometerIS1BX003970 · VA · VA BOSTON HEALTH CARE SYSTEM · fiscal years 2017Same name and institution; not confirmed by an ID
- Innate and Adaptive Anti-Myeloma ImmunityP01CA078378 · NCI · DANA-FARBER CANCER INST · fiscal years 2010 to 2014 · $361,924 awarded in 2014Same name and institution; not confirmed by an ID
- Homologous Recombination Mediates Genomic Instability and Progression in MyelomaR01CA124929 · NCI · DANA-FARBER CANCER INST · fiscal years 2008 to 2012 · $344,180 awarded in 2012Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:09 UTC. The ranking covers the 200 most relevant of 67 PubMed records, and a shared surname and initials can bring in a namesake. All 67 on PubMed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 20212,208 citationsRCR 120.1
- Antitumor activity of thalidomide in refractory multiple myeloma.N Engl J Med · 19992,122 citationsRCR 46.0
- 1,575 citationsRCR 84.7
- 1,433 citationsRCR 50.4
- Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.N Engl J Med · 20011,321 citationsRCR 28.6
- 1,045 citationsRCR 36.3
- 730 citationsRCR 17.8
- 492 citationsRCR 12.2
- 437 citationsRCR 9.7
- 433 citationsRCR 32.2